104 related articles for article (PubMed ID: 38720421)
1. Association between colchicine use and the risk of dementia among patients with gout: A nationwide retrospective cohort study.
Chen PY; Tseng CC; Lee YT; Yip HT; Chang R; Wei JC
Int J Rheum Dis; 2024 May; 27(5):e15162. PubMed ID: 38720421
[TBL] [Abstract][Full Text] [Related]
2. Association of gout medications and risk of cataract: a population-based case-control study.
Li YJ; Perng WT; Tseng KY; Wang YH; Wei JC
QJM; 2019 Nov; 112(11):841-846. PubMed ID: 31286139
[TBL] [Abstract][Full Text] [Related]
3. Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study.
Chuang JP; Lee JC; Leu TH; Hidajah AC; Chang YH; Li CY
BMJ Open; 2019 Oct; 9(10):e028892. PubMed ID: 31601586
[TBL] [Abstract][Full Text] [Related]
4. Effects of colchicine use on ischemic and hemorrhagic stroke risk in diabetic patients with and without gout.
Yeh JJ; Kuo IL; Yip HT; Hsueh MY; Hsu CY; Kao CH
Sci Rep; 2022 Jun; 12(1):9195. PubMed ID: 35655077
[TBL] [Abstract][Full Text] [Related]
5. Gout can increase the risk of periodontal disease in Taiwan.
Chen HH; Ho CW; Hsieh MC; Chen CC; Hsu SP; Lin CL; Kao CH
Postgrad Med; 2020 Aug; 132(6):521-525. PubMed ID: 32298158
[No Abstract] [Full Text] [Related]
6. Colchicine Significantly Reduces Incident Cancer in Gout Male Patients: A 12-Year Cohort Study.
Kuo MC; Chang SJ; Hsieh MC
Medicine (Baltimore); 2015 Dec; 94(50):e1570. PubMed ID: 26683907
[TBL] [Abstract][Full Text] [Related]
7. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims.
Solomon DH; Liu CC; Kuo IH; Zak A; Kim SC
Ann Rheum Dis; 2016 Sep; 75(9):1674-9. PubMed ID: 26582823
[TBL] [Abstract][Full Text] [Related]
8. Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout.
Wang L; Sawhney M; Zhao Y; Carpio GR; Fonseca V; Shi L
Clin Ther; 2015 Jun; 37(6):1206-15. PubMed ID: 25857595
[TBL] [Abstract][Full Text] [Related]
9. Association between Clinical Use of Colchicine and Risk of Type 2 Diabetes Mellitus among Gouty Patients: A Nationwide Cohort Study.
Chu CC; Chen YC; Lin MH; Wu WT; Liu FC; Chen HC; Chou YC; Sun CA
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35329085
[TBL] [Abstract][Full Text] [Related]
10. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
[TBL] [Abstract][Full Text] [Related]
11. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of cancer among gout patients: a nationwide population study.
Kuo CF; Luo SF; See LC; Chou IJ; Fang YF; Yu KH
Joint Bone Spine; 2012 Jul; 79(4):375-8. PubMed ID: 22088929
[TBL] [Abstract][Full Text] [Related]
13. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
[TBL] [Abstract][Full Text] [Related]
14. GOSPEL 2 - Colchicine for the treatment of gout flares in France - a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age.
Pascart T; Lancrenon S; Lanz S; Delva C; Guggenbuhl P; Lambert C; Aubert JP; Saraux A; Ea HK; Lioté F
Joint Bone Spine; 2016 Dec; 83(6):687-693. PubMed ID: 26919801
[TBL] [Abstract][Full Text] [Related]
15. Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink.
Roddy E; Bajpai R; Forrester H; Partington RJ; Mallen CD; Clarson LE; Padmanabhan N; Whittle R; Muller S
Ann Rheum Dis; 2023 Dec; 82(12):1618-1625. PubMed ID: 37788904
[TBL] [Abstract][Full Text] [Related]
16. Colchicine for acute gout.
van Echteld I; Wechalekar MD; Schlesinger N; Buchbinder R; Aletaha D
Cochrane Database Syst Rev; 2014 Aug; (8):CD006190. PubMed ID: 25123076
[TBL] [Abstract][Full Text] [Related]
17. Urate-lowering treatment and risk of total joint replacement in patients with gout.
Kuo CF; Chou IJ; See LC; Chen JS; Yu KH; Luo SF; Hsieh AH; Zhang W; Doherty M
Rheumatology (Oxford); 2018 Dec; 57(12):2129-2139. PubMed ID: 30060176
[TBL] [Abstract][Full Text] [Related]
18. Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
Fang YJ; Chung YL; Lin CL; Lim YP
Biomed Res Int; 2020; 2020():6358954. PubMed ID: 32775432
[TBL] [Abstract][Full Text] [Related]
19. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
[No Abstract] [Full Text] [Related]
20. The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan's National Health Insurance Research Database.
Yeh JJ; Liw PX; Wong YS; Kao HM; Lee CH; Lin CL; Kao CH
Eur J Med Res; 2024 Apr; 29(1):245. PubMed ID: 38649928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
